John D. Iuliucci

Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi et al. · Journal of Medicinal Chemistry · 2010 · 362 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with <i>in vivo</i> antiresorptive activity

William C. Shakespeare, Michael G. Yang, Regine S. Bohacek et al. · Proceedings of the National Academy of Sciences · 2000 · 133 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers

John D. Iuliucci, Stuart Oliver, Steven K. Morley et al. · The Journal of Clinical Pharmacology · 2001 · 125 citations

Medicine, Pharmacokinetics, Pharmacology +8

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

Victor M. Rivera, Rachel M. Squillace, David F. Miller et al. · Molecular Cancer Therapeutics · 2011 · 105 citations · Full text

Medicine, Oncology, Pharmacology +15

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold et al. · Blood · 2005 · 61 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +7